Overview
AXSM market data
Price History
AXSM price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.68 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.85 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -26.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $103.40 – $260.19 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $11.3B · P/B 71.94 · P/S 15.94.
Company News
Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $316Benzinga · Aug 12, 2026, 12:49 PM
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $251Benzinga · Aug 11, 2026, 3:50 PM
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $297Benzinga · Aug 11, 2026, 3:13 PM
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 ResultsBenzinga · Aug 11, 2026, 2:30 PM
Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $275Benzinga · Aug 11, 2026, 2:22 PM
Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $256Benzinga · Aug 11, 2026, 1:08 PM
Target To Rally Around 12%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga · Aug 11, 2026, 11:59 AM
Needham Maintains Buy on Axsome Therapeutics, Raises Price Target to $268Benzinga · Aug 11, 2026, 10:24 AM
8-K filing — Axsome Therapeutics, Inc. (AXSM)SEC EDGAR · Aug 10, 2026, 11:05 AM
Axsome Therapeutics Q2 EPS $(0.99) Misses $(0.83) Estimate, Sales $218.400M Miss $221.230M EstimateBenzinga · Aug 10, 2026, 11:01 AM